TABLE 1.
Demographic and clinical characteristics of the cohort
| SOTR dose 2(N = 58), n (%) | SOTR dose 3(N = 35), n (%) | P a | HC (N = 16), n (%) | |
|---|---|---|---|---|
| Age | ||||
| 20–39 | 15 (26) | 3 (9) | 0.108 | 7 (44) |
| 40–59 | 15 (26) | 13 (37) | 9 (56) | |
| 60–79 | 28 (48) | 19 (54) | 0 (0) | |
| Sex | ||||
| Female | 31 (53) | 19 (54) | 1.000 | 5 (31) |
| Male | 27 (47) | 16 (46) | 11 (69) | |
| Race | ||||
| White | 53 (91) | 33 (94) | 0.417 | 11 (69) |
| Asian | 3 (5) | 0 (0) | 3 (19) | |
| African American | 1 (2) | 0 (0) | 2 (13) | |
| Multiple race | 1 (2) | 1 (3) | 0 (0) | |
| Other | 0 (0) | 1 (3) | 0 (0) | |
| Type of vaccine received | ||||
| First 2 doses | ||||
| BNT162b2 | 33 (57) | 17 (49) | 0.665 | – |
| mRNA-1273 | 25 (43) | 17 (49) | – | |
| Missing | 0 (0) | 1 (3) | – | |
| Third dose | ||||
| BNT162b2 | – | 8 (23) | – | – |
| mRNA-1273 | – | 14 (40) | – | |
| Ad26.COV2.S | – | 13 (37) | – | |
| Graft transplanted | ||||
| Kidney | 37 (67) | 19 (54) | 0.815 | – |
| Heart | 5 (9) | 3 (9) | – | |
| Liver | 12 (21) | 9 (26) | – | |
| Lung | 2 (3) | 1 (3) | – | |
| Pancreas | 0 (0) | 1 (3) | – | |
| Multib | 2 (0) | 1 (3) | – | |
| Antirejection medicationc | ||||
| Prednisone | 38 (66) | 17 (49) | 0.130 | – |
| Calcineurin Inhibitors | 52 (90) | 28 (80) | 0.226 | – |
| mTOR inhibitors | 8 (14) | 3 (9) | 0.526 | – |
| Antimetabolites | 40 (69) | 23 (66) | 0.820 | – |
| Treated for rejection in the past 6 mo | ||||
| Not treated | 52 (90) | 32 (91) | 1.000 | – |
| Was treated | 3 (5) | 1 (3) | – | |
| Missing | 3 (5) | 2 (6) | – | |
| Postvaccine SARS-CoV-2 IgG | ||||
| Negative | 24 (41) | 13 (37) | 0.827 | 0 (0) |
| Positive | 34 (59) | 22 (63)d | 16 (100) | |
| Low titer | 32 (55) | 19 (54) | 1.000 | 0 (0) |
| High titer | 26 (45) | 16 (46) | 16 (100) |
One participant was included in both SOTR dose 2 cohort and SOTR dose 3 cohort.
aP-value comparing SOTR dose 2 and SOTR dose 3 cohort were computed using 2-tailed Fisher’s exact test.
bIn the SOTR dose 2 cohort, 1 participant received both kidney and heart transplants, and 1 participant received both kidney and liver transplants; in the SOTR dose 3 cohort, 1 participant received both kidney and pancreas transplants, and 1 participant received both lung and other specified transplant.
cAntirejection medication use was not mutually exclusive.
dSix participants in the dose 3 cohort were seropositive before receiving a third dose.
HC, healthy control; IgG, immunoglobulin G; mRNA, mRNA; mTOR, mechanistic target of rapamycin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOTR, solid organ transplant recipient.